Trinity Biotech (TRIB)
(Real Time Quote from BATS)
$1.24 USD
-0.04 (-3.13%)
Updated Sep 20, 2024 03:49 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Income Statements
Fiscal Year end for Trinity Biotech PLC falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 57 | 75 | 93 | 102 | 90 |
Cost Of Goods | 37 | 53 | 55 | 53 | 52 |
Gross Profit | 19 | 22 | 38 | 49 | 38 |
Selling & Adminstrative & Depr. & Amort Expenses | 47 | 39 | 31 | 49 | 62 |
Income After Depreciation & Amortization | -27 | -17 | 7 | 0 | -24 |
Non-Operating Income | 1 | 0 | 1 | 0 | 1 |
Interest Expense | 11 | 25 | 7 | 7 | 7 |
Pretax Income | -37 | -41 | 1 | -7 | -30 |
Income Taxes | 0 | 0 | 0 | -1 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -37 | -41 | 1 | -6 | -29 |
Extras & Discontinued Operations | 13 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -24 | -41 | 1 | -6 | -29 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -25 | -14 | 9 | 3 | -19 |
Depreciation & Amortization (Cash Flow) | 2 | 2 | 3 | 3 | 5 |
Income After Depreciation & Amortization | -27 | -17 | 7 | 0 | -24 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 7.66 | 6.75 | 5.33 | 5.25 | 5.09 |
Diluted EPS Before Non-Recurring Items | -3.37 | -5.25 | 1.75 | 3.75 | -0.15 |
Diluted Net EPS (GAAP) | -3.14 | -6.10 | 0.20 | -1.55 | -6.90 |
Fiscal Year end for Trinity Biotech PLC falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 15.84 | 14.70 | 13.43 | 14.68 | 13.90 |
Cost Of Goods | 10.11 | 9.18 | 8.86 | 10.40 | 8.87 |
Gross Profit | 5.73 | 5.52 | 4.57 | 4.28 | 5.03 |
SG&A, R&D, and Dept/Amort Expenses | 9.78 | 8.56 | 8.34 | 8.78 | 19.88 |
Income After SG&A, R&D, and Dept/Amort Expenses | -4.05 | -3.04 | -3.77 | -4.50 | -14.85 |
Non-Operating Income | 0.00 | 0.06 | 0.57 | 0.39 | 0.06 |
Interest Expense | 2.84 | 0.26 | 2.29 | 2.39 | 3.82 |
Pretax Income | -6.89 | -3.25 | -5.50 | -6.50 | -18.61 |
Income Taxes | -0.13 | 0.07 | 0.00 | 0.22 | -0.27 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -6.76 | -3.32 | -5.50 | -6.72 | -18.35 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 12.36 |
Net Income (GAAP) | -6.76 | -3.32 | -5.50 | -6.72 | -5.99 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 9.47 | 8.87 | 7.67 | 7.67 | 7.66 |
Diluted EPS Before Non-Recurring Items | -0.55 | -0.37 | -0.68 | -0.90 | -1.00 |
Diluted Net EPS (GAAP) | -0.71 | -0.37 | -0.73 | -0.88 | -0.78 |